Todas as matérias desta seção, das mais recentes às mais antigas — página 251 de 371.
Nebius Group (NASDAQ:NBIS) announced a strategic collaboration with Nvidia (NASDAQ:NVDA) to accelerate the development of physical artificial intelligence, providing a unified platform for the entire robotics lifecycle.
Llulemon athletica (NASDAQ:LULU) announced its financial results for the fourth quarter and fiscal year ended February 1, 2026, revealing a tale of two markets.
Titan America (NYSE:TTAM) announced today its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a period of sustained growth and operational efficiency.
Docusign (NASDAQ:DOCU) reported robust financial results for its fourth quarter and fiscal year ended January 31, 2026, demonstrating its resilience as it evolves beyond simple e-signatures into a comprehensive agreement management powerhouse.
High Tide (NASDAQ:HITI) reported its financial results for the first fiscal quarter ended January 31, 2026, marking its strongest start to a fiscal year to date.
Oklo (NYSE:OKLO) shares surged as much as 7% Tuesday before paring gains after the nuclear technology developer announced a safety design agreement with the U.S. Department of Energy to support the design, construction and operation of its first Aurora reactor at Idaho National Laboratory.
Coda Octopus Group (NASDAQ:CODA) reported robust financial results for its fiscal first quarter ended January 31, 2026, highlighting a period of accelerated growth for its high-definition underwater imaging platforms.
Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology firm pioneering "Bicycle" peptide technology, reported its fourth-quarter and full-year 2025 financial results on March 17, 2026.
General Mills (NYSE:GIS) announced today that it has entered into a definitive agreement to divest its operations in Brazil to Grupo 3corações, a leading Brazilian food and beverage company.
Gyre Therapeutics (NASDAQ:GYRE) reached a critical regulatory milestone as the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) granted Priority Review status to the New Drug Application (NDA) for Hydronidone (F351).
Kalaris (NASDAQ:KLRS) reported its fourth-quarter and full-year 2025 financial results today, delivering a clinical update that positions its lead candidate as a potential disruptor in the $13 billion anti-VEGF market.
Expion360 (NASDAQ:XPON) on Tuesday reported full-year 2025 net sales of $9.7 million for the period ended December 31, 2025, an increase of 72% from the prior year, reflecting continued expansion in lithium battery solutions for recreational vehicles, marine and industrial applications.
Comstock Holding Companies (NASDAQ:CHCI) reported robust financial results for the fourth quarter and full year ended December 31, 2025, extending its streak of year-over-year revenue growth to 28 consecutive quarters.
Lifeway Foods (NASDAQ:LWAY) reported a strong conclusion to its 2025 fiscal year, fueled by consistent volume growth across its core probiotic dairy portfolio.
IceCure Medical (NASDAQ:ICCM) announced record financial results for the fourth quarter and full year ended December 31, 2025, marking a transformative period for the Israeli medtech firm.
Academy Sports + Outdoors (NASDAQ:ASO) reported a solid conclusion to fiscal 2025, with full-year net sales climbing 2% to reach a milestone of $6.05 billion.
Telesat (NASDAQ:TSAT) reported a net loss of $90.1 million for the fourth quarter ended December 31, 2025.
Mastercard (NYSE:MA) today signaled a major shift in the global payments landscape by announcing the acquisition of BVNK, a prominent provider of stablecoin and digital asset infrastructure.
Neuronetics (NASDAQ:STIM), the leader in Transcranial Magnetic Stimulation (TMS) therapy for mental health, reported its fourth-quarter and full-year 2025 financial results, reflecting the transformative impact of its late-2024 acquisition of Greenbrook TMS.
Corporación América Airports (NYSE:CAAP), one of the world's largest private airport operators, delivered a strong finish to fiscal 2025, characterized by robust top-line growth and a dramatic expansion in profitability.
CervoMed (NASDAQ:CRVO) announced on Tuesday that it has achieved critical regulatory and clinical alignment for the Phase 3 development of neflamapimod, its oral small-molecule treatment for dementia with Lewy bodies (DLB).
Abeona Therapeutics (NASDAQ:ABEO) on Wednesday reported financial results for the full year ended December 31, 2025, and provided operational updates centered on the commercial launch of its lead gene therapy ZEVASKYN.
X4 Pharmaceuticals (NASDAQ:XFOR) reported its fourth-quarter and full-year 2025 financial results on March 17, 2026, marking a year of transition from a clinical-stage entity to a commercial-revenue-generating firm.
Victory Capital Holdings (NASDAQ:VCTR) increased the pressure on Janus Henderson Group (NYSE:JHG) today, submitting an enhanced acquisition proposal to the company’s Special Committee.
